Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Conditions: Early-stage Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Invasive Breast Cancer; Stage II Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer Interventions: Drug: Anastrozole; Procedure: Therapeutic Conventional Surgery; Biological: Trastuzumab Deruxtecan Sponsors: Jonsson Comprehensive Cancer Center; Translational Research in Oncology-U.S; Daiichi Sankyo Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Arimidex | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | HER2 | Herceptin | Hormones | Research